Welcome to our dedicated page for Heska news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on Heska stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heska's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heska's position in the market.
Heska Corporation (NASDAQ: HSKA) reported a strong third quarter for 2020, achieving consolidated revenue of $56.6 million, up 81.3% year-over-year. North America revenue rose 16.4% to $34.4 million, while international revenue reached $22.2 million. Despite a net loss of $5.2 million and a diluted EPS of $(0.57), the adjusted EBITDA margin improved to 15.3%. The results were boosted by robust sales in Point of Care (POC) Lab Consumables, particularly in North America. The company anticipates continued growth and plans to discuss future strategies at its Investor Day on November 18.
Heska Corporation (NASDAQ: HSKA), a key player in veterinary diagnostics and specialty products, will announce its third quarter 2020 financial results on November 5, 2020, before the market opens. An earnings call will follow at 9 a.m. MT to discuss the results. Interested parties can join the call via phone or listen through a live webcast. Heska specializes in advanced veterinary diagnostics, offering products including lab testing instruments, digital imaging, and allergy testing.
Heska Corporation (NASDAQ: HSKA) will host its 2020 Investor Day virtually on November 18, 2020, at 9:00 a.m. MT (11:00 a.m. ET). The event will feature presentations discussing Heska's strategic vision, global veterinary health market role, and financial targets.
Key participants include CEO Kevin Wilson and COO Nancy Wisnewski. Attendees can register for the event through Heska's website, and a replay of the event will be available for 90 days. This update comes after a rescheduling from the original date of November 12, 2020.
Heska Corporation (NASDAQ: HSKA) appointed Stephen Davis to its Board of Directors effective August 20, 2020. Davis, founder of the Will Group, brings substantial leadership experience and operational expertise, particularly in supply-chain logistics and international manufacturing. Board Chair Scott Humphrey emphasized Davis's strong business acumen, which aligns with Heska's strategic goals. Davis expressed enthusiasm about contributing to the company's mission of enhancing pet health and shareholder value. Heska specializes in advanced veterinary diagnostics and specialty healthcare products across North America and internationally.
Heska Corporation (NASDAQ: HSKA) reported robust Q2 2020 results, achieving $45.7 million in consolidated revenue, a 62.4% increase year-over-year. North America revenue rose by 9.8% to $29.0 million, while international revenue reached $16.7 million. Despite a net loss of $(6.4 million) due to acquisition-related costs, adjusted EBITDA margin improved to 9.1%. The company announced a revised 2020 revenue outlook of $175-$185 million. CEO Kevin Wilson expressed confidence in achieving strategic goals despite market challenges.